{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:17:13Z","timestamp":1792120633141,"version":"4.4.0"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08299-4","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T05:37:52Z","timestamp":1779860272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Yulin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haobo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5634","authenticated-orcid":false,"given":"Dongbo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"7","key":"8299_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321. https:\/\/doi.org\/10.1038\/s41571-024-00903-0.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"8299_CR2","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie T, Tiruneh G\/Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega WChekol Abebe E. Chekol Abebe E: current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccines Immunotherapeutics. 2022;18(6):2114254. https:\/\/doi.org\/10.1080\/21645515.2022.2114254.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"23","key":"8299_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-Cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2406526.","journal-title":"N Engl J Med"},{"key":"8299_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","volume":"319","author":"TR Abreu","year":"2020","unstructured":"Abreu TR, Fonseca NA, Gon N, Moreira JON. Current challenges and emerging opportunities of CAR-T cell therapies. J Control Release. 2020;319:246\u201361. https:\/\/doi.org\/10.1016\/j.jconrel.2019.12.047.","journal-title":"J Control Release"},{"key":"8299_CR5","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, et al. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58:102931. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","journal-title":"EBioMedicine"},{"issue":"4","key":"8299_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/bloodadvances.2024015763","volume":"10","author":"Y Xie","year":"2026","unstructured":"Xie Y, Zhou K, Li L, Liang A, Mei H, Zou D, et al. Phase 2 study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed\/Refractory mantle cell lymphoma in Chinese adults. Blood Adv. 2026;10(4):1134\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2024015763.","journal-title":"Blood Adv"},{"issue":"5","key":"8299_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","volume":"38","author":"LM Schultz","year":"2024","unstructured":"Schultz LM, Jeyakumar N, Kramer AM, Sahaf B, Srinagesh H, Shiraz P, et al. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results. Leukemia. 2024;38(5):963\u201368. https:\/\/doi.org\/10.1038\/s41375-024-02220-y.","journal-title":"Leukemia"},{"issue":"3","key":"8299_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","volume":"8","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, et al. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802\u201314. https:\/\/doi.org\/10.1182\/bloodadvances.2023011470.","journal-title":"Blood Adv"},{"issue":"8","key":"8299_CR9","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224\u201334. https:\/\/doi.org\/10.1038\/s41591-024-03037-z.","journal-title":"Nat Med"},{"issue":"1","key":"8299_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 2024;10(1):49. https:\/\/doi.org\/10.1038\/s41421-024-00658-z.","journal-title":"Cell Discov"},{"issue":"18","key":"8299_CR11","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890\u2013904.e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027.","journal-title":"Cell"},{"issue":"24","key":"8299_CR12","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A Pecher","year":"2023","unstructured":"Pecher A, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154. https:\/\/doi.org\/10.1001\/jama.2023.8753.","journal-title":"JAMA"},{"issue":"6","key":"8299_CR13","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41590-024-01834-9","volume":"25","author":"G Jin","year":"2024","unstructured":"Jin G, Liu Y, Wang L, He Z, Zhao X, Ma Y, et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat Immunol. 2024;25(6):1059\u201372. https:\/\/doi.org\/10.1038\/s41590-024-01834-9.","journal-title":"Nat Immunol"},{"issue":"6","key":"8299_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41590-024-01851-8","volume":"25","author":"BN Lambrecht","year":"2024","unstructured":"Lambrecht BN, Hammad H. CAR T cells put the brakes on asthma. Nat Immunol. 2024;25(6):935\u201337. https:\/\/doi.org\/10.1038\/s41590-024-01851-8.","journal-title":"Nat Immunol"},{"issue":"7","key":"8299_CR15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski K, Hill JA, Dahiya S, Jain MD. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025;31(7):2132\u201346. https:\/\/doi.org\/10.1038\/s41591-025-03813-5.","journal-title":"Nat Med"},{"issue":"3","key":"8299_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11684-025-1130-x","volume":"19","author":"Y Huang","year":"2025","unstructured":"Huang Y, Wang H. Tonic signaling in CAR-T therapy: the lever long enough to move the planet. Front Med. 2025;19(3):391\u2013408. https:\/\/doi.org\/10.1007\/s11684-025-1130-x.","journal-title":"Front. Med"},{"issue":"1","key":"8299_CR17","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","volume":"15","author":"I Andreu-Saumell","year":"2024","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J, et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15(1):3552. https:\/\/doi.org\/10.1038\/s41467-024-47799-z.","journal-title":"Nat Commun"},{"issue":"1","key":"8299_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022;20(1):239. https:\/\/doi.org\/10.1186\/s12967-022-03442-3.","journal-title":"J Transl Med"},{"key":"8299_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2021.09.007","volume":"73","author":"J Eggert","year":"2021","unstructured":"Eggert J, Au-Yeung BB. Functional heterogeneity and adaptation of naive T cells in response to tonic TCR signals. Curr Opin Immunol. 2021;73:43\u201349. https:\/\/doi.org\/10.1016\/j.coi.2021.09.007.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"8299_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick MB, Silva H, Scarf\u00f2 I, Larson R, Choi BD, Bouffard AA, et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell. 2022;40(5):494\u2013508.e5. https:\/\/doi.org\/10.1016\/j.ccell.2022.04.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"8299_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12943-024-02154-0","volume":"23","author":"C Zhang","year":"2024","unstructured":"Zhang C, Liu T, Li S, Teng X, Zhu Y, Zhang G, et al. Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy. Mol Cancer. 2024;23(1):236. https:\/\/doi.org\/10.1186\/s12943-024-02154-0.","journal-title":"Mol Cancer"},{"key":"8299_CR22","doi-asserted-by":"publisher","unstructured":"Barbera S, Schuiling MJA, Sanjaya NA, Pietil\u00e4 I, Sar\u00e9n T, Essand M, et al. Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains. Sci Immunol. 2025;10: eado 2054.103). https:\/\/doi.org\/10.1126\/sciimmunol.ado2054.","DOI":"10.1126\/sciimmunol.ado2054"},{"issue":"3","key":"8299_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145\u201361. https:\/\/doi.org\/10.1038\/s41568-020-00323-z.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"8299_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jitc-2024-010530","volume":"13","author":"SH Olejniczak","year":"2025","unstructured":"Olejniczak SH, Lotze MT, Skokos D. Second signals for cancer immunotherapy. J Immunother Cancer. 2025;13(9):13. https:\/\/doi.org\/10.1136\/jitc-2024-010530.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"8299_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","volume":"24","author":"MT Lotze","year":"2024","unstructured":"Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol. 2024;24(12):878\u201395. https:\/\/doi.org\/10.1038\/s41577-024-01061-1.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"8299_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jitc-2021-003354","volume":"9","author":"E Roselli","year":"2021","unstructured":"Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J Immunother Cancer. 2021;9(10):9. https:\/\/doi.org\/10.1136\/jitc-2021-003354.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8299_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/1078-0432.CCR-18-1211","volume":"25","author":"CM Suryadevara","year":"2019","unstructured":"Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, et al. Preventing lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts. Clin Cancer Res. 2019;25(1):358\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1211.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8299_CR28","doi-asserted-by":"publisher","first-page":"189519","DOI":"10.1016\/j.bbcan.2025.189519","volume":"1881","author":"M Krawczyk","year":"2026","unstructured":"Krawczyk M, Dru\u017cy\u0144ska M, Bednarska E, Winiarska M. The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies. Biochim et Biophys Acta (BBA) - Rev Cancer. 2026;1881(1):189519. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189519.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"4","key":"8299_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2023-008429","volume":"12","author":"W Ouyang","year":"2024","unstructured":"Ouyang W, Jin S, Xu N, Liu W, Zhao H, Zhang L, et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):12. https:\/\/doi.org\/10.1136\/jitc-2023-008429.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"8299_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biom12091303","volume":"12","author":"MM Honikel","year":"2022","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules. 2022;12(9):12. https:\/\/doi.org\/10.3390\/biom12091303.","journal-title":"Biomolecules"},{"issue":"1","key":"8299_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-immunol-082423-040557","volume":"43","author":"TH Watts","year":"2025","unstructured":"Watts TH, Yeung KKM, Yu T, Lee S, Eshraghisamani R. TNF\/TNFR superfamily members in costimulation of T cell responses\u2014revisited. Annu Rev Immunol. 2025;43(1):113\u201342. https:\/\/doi.org\/10.1146\/annurev-immunol-082423-040557.","journal-title":"Annu. Rev. Immunol"},{"issue":"1","key":"8299_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1186\/s12967-025-06718-6","volume":"23","author":"M Guo","year":"2025","unstructured":"Guo M, Zhang Y, Yuan X, Wang X. Innovative approaches to CAR-T cell therapy: the role of lipid metabolism pathways. J Transl Med. 2025;23(1):670. https:\/\/doi.org\/10.1186\/s12967-025-06718-6.","journal-title":"J Transl Med"},{"issue":"5","key":"8299_CR33","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo C, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7(5):759\u201372. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0466.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"8299_CR34","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","volume":"31","author":"L Tang","year":"2023","unstructured":"Tang L, Pan S, Wei X, Xu X, Wei Q. Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development. Mol Ther. 2023;31(11):3146\u201362. https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.021.","journal-title":"Mol Ther"},{"issue":"12","key":"8299_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","volume":"40","author":"A Smole","year":"2022","unstructured":"Smole A, Benton A, Poussin MA, Eiva MA, Mezzanotte C, Camisa B, et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell. 2022;40(12):1470\u201387.e7. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.006.","journal-title":"Cancer Cell"},{"issue":"3","key":"8299_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/medsci13030190","volume":"13","author":"SA Rabbani","year":"2025","unstructured":"Rabbani SA, El-Tanani M, El-Tanani Y, Kumar R, Sharma S, Khan MA, et al. Advances in adoptive cell therapies in Cancer: from mechanistic breakthroughs to clinical frontiers and Overcoming barriers. Med Sci. 2025;13(3):13. https:\/\/doi.org\/10.3390\/medsci13030190.","journal-title":"Med Sci"},{"issue":"3","key":"8299_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang C, Saso K, et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352\u201359. https:\/\/doi.org\/10.1038\/nm.4478.","journal-title":"Nat Med"},{"key":"8299_CR38","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.ebiom.2024.105266","volume":"106","author":"TA Bui","year":"2024","unstructured":"Bui TA, Mei H, Sang R, Ortega DG, Deng W. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine. 2024;106:105266. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105266.","journal-title":"EBioMedicine"},{"issue":"11","key":"8299_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.molmed.2025.05.011","volume":"31","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Wu B, Zhou Q, Wu F, Li N, Xu C, et al. Technologies for chimeric antigen receptor transgene delivery. Trends Mol Med. 2025;31(11):1047\u201364. https:\/\/doi.org\/10.1016\/j.molmed.2025.05.011.","journal-title":"Trends Mol Med"},{"issue":"5","key":"8299_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short L, Holt RA, Cullis PR, Evgin L. Direct in vivo CAR T cell engineering. Trends Pharmacological Sci. 2024;45(5):406\u201318. https:\/\/doi.org\/10.1016\/j.tips.2024.03.004.","journal-title":"Trends Pharmacological Sci"},{"issue":"8","key":"8299_CR41","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/s41423-025-01314-6","volume":"22","author":"Q Zhu","year":"2025","unstructured":"Zhu Q, Li J, Liu N, Han L, Wu Z, Wang Y, et al. CD2 augmentation enhances CAR-T-cell efficacy via immunological synapse remodeling and T-cell exhaustion mitigation. Cell Mol Immunol. 2025;22(8):935\u201348. https:\/\/doi.org\/10.1038\/s41423-025-01314-6.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8299_CR42","doi-asserted-by":"publisher","first-page":"7987","DOI":"10.1038\/s41467-025-63184-w","volume":"16","author":"G Nam","year":"2025","unstructured":"Nam G, Yeon HR, Park HB, Chang H, Kim JH, Cho B, et al. CD99-mediated immunological synapse formation potentiates CAR-T cell function. Nat Commun. 2025;16(1):7987. https:\/\/doi.org\/10.1038\/s41467-025-63184-w.","journal-title":"Nat Commun"},{"issue":"1","key":"8299_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao Z, Mei Q, Yang C, Luo J, Liu P, Peng H, et al. Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Sig Transduct Target Ther. 2025;10(1):254. https:\/\/doi.org\/10.1038\/s41392-025-02332-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"7","key":"8299_CR44","doi-asserted-by":"publisher","first-page":"112663","DOI":"10.1016\/j.celrep.2023.112663","volume":"42","author":"W Huang","year":"2023","unstructured":"Huang W, Lin W, Chen B, Zhang J, Gao P, Fan Y, et al. NFAT and NF-\u03baB dynamically co-regulate TCR and CAR signaling responses in human T cells. Cell Rep. 2023;42(7):112663. https:\/\/doi.org\/10.1016\/j.celrep.2023.112663.","journal-title":"Cell Rep"},{"issue":"1","key":"8299_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"key":"8299_CR46","doi-asserted-by":"publisher","first-page":"756599","DOI":"10.3389\/fmolb.2021.756599","volume":"8","author":"Y Nai","year":"2021","unstructured":"Nai Y, Du L, Shen M, Li T, Huang J, Han X, et al. TRAIL-R1-Targeted CAR-T cells exhibit dual antitumor efficacy. Front Mol Biosci. 2021;8:756599. https:\/\/doi.org\/10.3389\/fmolb.2021.756599.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"8299_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41419-024-06461-8","volume":"15","author":"MJ Montalvo","year":"2024","unstructured":"Montalvo MJ, Bandey IN, Rezvan A, Wu K, Saeedi A, Kulkarni R, et al. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death Dis. 2024;15(2):109. https:\/\/doi.org\/10.1038\/s41419-024-06461-8.","journal-title":"Cell Death Dis"},{"issue":"2","key":"8299_CR48","doi-asserted-by":"publisher","first-page":"100917","DOI":"10.1016\/j.xcrm.2023.100917","volume":"4","author":"L Wu","year":"2023","unstructured":"Wu L, Brzostek J, Sakthi Vale PD, Wei Q, Koh CKT, Ong JXH, et al. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. Cell Rep. Med. 2023;4(2):100917. https:\/\/doi.org\/10.1016\/j.xcrm.2023.100917.","journal-title":"Cell Rep. Med"},{"issue":"5","key":"8299_CR49","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10(5):702\u201323. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0945.","journal-title":"Cancer Discov"},{"issue":"7952","key":"8299_CR50","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim W, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature. 2023;615(7952):507\u201316. https:\/\/doi.org\/10.1038\/s41586-023-05778-2.","journal-title":"Nature"},{"key":"8299_CR51","doi-asserted-by":"publisher","unstructured":"Dong R, Libby KA, Blaeschke F, Fuchs W, Marson A, Vale RD, et al. Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR). Embo J. 2020;39(16):e104730. https:\/\/doi.org\/10.15252\/embj.2020104730.","DOI":"10.15252\/embj.2020104730"},{"key":"8299_CR52","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.smim.2020.101434","volume":"49","author":"X Meng","year":"2020","unstructured":"Meng X, Wu X, Zheng Y, Shang K, Jing R, Jiao P, et al. Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy. Semin Immunol. 2020;49:101434. https:\/\/doi.org\/10.1016\/j.smim.2020.101434.","journal-title":"Semin Immunol"},{"issue":"544","key":"8299_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter AI, Ivey RG, Kennedy JJ, Voillet V, Rajan A, Alderman EJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):11. https:\/\/doi.org\/10.1126\/scisignal.aat6753.","journal-title":"Sci Signal"},{"issue":"10","key":"8299_CR54","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1016\/j.ymthe.2024.08.028","volume":"32","author":"I Ajmal","year":"2024","unstructured":"Ajmal I, Farooq MA, Duan Y, Yao J, Gao Y, Hui X, et al. Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer. Mol Ther. 2024;32(10):3539\u201357. https:\/\/doi.org\/10.1016\/j.ymthe.2024.08.028.","journal-title":"Mol Ther"},{"issue":"8","key":"8299_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24087373","volume":"24","author":"SJ Harwood","year":"2023","unstructured":"Harwood SJ, Smith CR, Lawson JD, Ketcham JM. Selected approaches to disrupting protein\u2013protein interactions within the MAPK\/RAS pathway. IJMS. 2023;24(8):24. https:\/\/doi.org\/10.3390\/ijms24087373.","journal-title":"IJMS"},{"issue":"3","key":"8299_CR56","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ccell.2025.02.008","volume":"43","author":"C Pham-Danis","year":"2025","unstructured":"Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, et al. Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025;43(3):482\u2013502.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.008.","journal-title":"Cancer Cell"},{"issue":"8","key":"8299_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud G, Lesourne R, Love PE. Regulatory mechanisms in T cell receptor signalling. Nat Rev Immunol. 2018;18(8):485\u201397. https:\/\/doi.org\/10.1038\/s41577-018-0020-8.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"8299_CR58","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Sig Transduct Target Ther. 2021;6(1):412. https:\/\/doi.org\/10.1038\/s41392-021-00823-w.","journal-title":"Sig Transduct Target Ther"},{"issue":"9","key":"8299_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41389-021-00353-8","volume":"10","author":"Y Gao","year":"2021","unstructured":"Gao Y, Lin H, Guo D, Cheng S, Zhou Y, Zhang L, et al. Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway. Oncogenesis. 2021;10(9):62. https:\/\/doi.org\/10.1038\/s41389-021-00353-8.","journal-title":"Oncogenesis"},{"issue":"2","key":"8299_CR60","doi-asserted-by":"publisher","first-page":"101970","DOI":"10.1016\/j.xcrm.2025.101970","volume":"6","author":"E Adabi","year":"2025","unstructured":"Adabi E, Charitidis FT, Thalheimer FB, Guaza-Lasheras M, Clarke C, Buchholz CJ. Enhanced conversion of T cells into CAR T cells by modulation of the MAPK\/ERK pathway. Cell Rep. Med. 2025;6(2):101970. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101970.","journal-title":"Cell Rep. Med"},{"issue":"4","key":"8299_CR61","doi-asserted-by":"publisher","first-page":"101023","DOI":"10.1016\/j.isci.2020.101023","volume":"23","author":"JA Rohrs","year":"2020","unstructured":"Rohrs JA, Siegler EL, Wang P, Finley SD. ERK activation in CAR T cells is amplified by CD28-mediated increase in CD3\u03b6 phosphorylation. iScience. 2020;23(4):101023. https:\/\/doi.org\/10.1016\/j.isci.2020.101023.","journal-title":"iScience"},{"issue":"2","key":"8299_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez GJ, Pereira RM, \u00c4ij\u00f6 T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity. 2015;42(2):265\u201378. https:\/\/doi.org\/10.1016\/j.immuni.2015.01.006.","journal-title":"Immunity"},{"issue":"25","key":"8299_CR63","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo H, Chen J, Gonz\u00e1lez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8 + T cell exhaustion. Proc Natl Acad Sci USA. 2019;116(25):12410\u201315. https:\/\/doi.org\/10.1073\/pnas.1905675116.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"8299_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","volume":"24","author":"A Mulvey","year":"2025","unstructured":"Mulvey A, Trueb L, Coukos G, Arber C. Novel strategies to manage CAR-T cell toxicity. Nat Rev Drug Discov. 2025;24(5):379\u201397. https:\/\/doi.org\/10.1038\/s41573-024-01100-5.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"8299_CR65","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1038\/s43018-025-01056-4","volume":"6","author":"MC Rotiroti","year":"2025","unstructured":"Rotiroti MC, Tousley AM, Chu H, Herrera-Barrera M, Manousopoulou A, Kim W, et al. Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy. Nat Cancer. 2025;6(12):1940\u201354. https:\/\/doi.org\/10.1038\/s43018-025-01056-4.","journal-title":"Nat Cancer"},{"issue":"625","key":"8299_CR66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1126\/scisignal.aay8248","volume":"13","author":"BI Philipson","year":"2020","unstructured":"Philipson BI, O\u2019Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci Signal. 2020;13(625):13. https:\/\/doi.org\/10.1126\/scisignal.aay8248.","journal-title":"Sci Signal"},{"issue":"3","key":"8299_CR67","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41423-023-01120-y","volume":"21","author":"S Liang","year":"2024","unstructured":"Liang S, Zheng R, Zuo B, Li J, Wang Y, Han Y, et al. SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell Mol Immunol. 2024;21(3):213\u201326. https:\/\/doi.org\/10.1038\/s41423-023-01120-y.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"8299_CR68","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41423-024-01198-y","volume":"21","author":"Z Dou","year":"2024","unstructured":"Dou Z, Bonacci TR, Shou P, Landoni E, Woodcock MG, Sun C, et al. 4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20. Cell Mol Immunol. 2024;21(8):905\u201317. https:\/\/doi.org\/10.1038\/s41423-024-01198-y.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8299_CR69","doi-asserted-by":"publisher","first-page":"2611615","DOI":"10.1080\/2162402X.2025.2611615","volume":"15","author":"M Lim","year":"2026","unstructured":"Lim M, Jung S, Koh C, Jeong H, Moon Y, Seo H. The LXR\u03b2\/NF-\u03baB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment. Oncoimmunology. 2026;15(1):2611615. https:\/\/doi.org\/10.1080\/2162402X.2025.2611615.","journal-title":"Oncoimmunology"},{"issue":"9","key":"8299_CR70","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1007\/s00432-022-04509-w","volume":"149","author":"L Liu","year":"2023","unstructured":"Liu L, Cheng Y, Zhang F, Chen J, Tian P, Shi W, et al. IL-2\/GM-CSF enhances CXCR3 expression in CAR-T cells via the PI3K\/AKT and ERK1\/2 pathways. J Cancer ResearchClin Oncol. 2023;149(9):5547\u201357. https:\/\/doi.org\/10.1007\/s00432-022-04509-w.","journal-title":"J Cancer ResearchClin Oncol"},{"issue":"1","key":"8299_CR71","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6.","journal-title":"Mol Cancer"},{"key":"8299_CR72","doi-asserted-by":"publisher","first-page":"108667","DOI":"10.1016\/j.pharmthera.2024.108667","volume":"259","author":"R Ramapriyan","year":"2024","unstructured":"Ramapriyan R, Vykunta VS, Vandecandelaere G, Richardson LGK, Sun J, Curry WT, et al. Altered cancer metabolism and implications for next-generation CAR T-cell therapies. Pharmacol Ther. 2024;259:108667. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108667.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"8299_CR73","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","volume":"5","author":"R Urak","year":"2017","unstructured":"Urak R, Walter M, Lim L, Wong CW, Budde LE, Thomas S, et al. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer. 2017;5(1):26. https:\/\/doi.org\/10.1186\/s40425-017-0227-4.","journal-title":"J Immunother Cancer"},{"issue":"88","key":"8299_CR74","doi-asserted-by":"publisher","first-page":"35807","DOI":"10.18632\/oncotarget.26334","volume":"9","author":"W Zheng","year":"2018","unstructured":"Zheng W, Jones LL, Geiger TL. Modulation of PI3K signaling to improve CAR T cell function. Oncotarget. 2018;9(88):35807\u201308. https:\/\/doi.org\/10.18632\/oncotarget.26334.","journal-title":"Oncotarget"},{"issue":"11","key":"8299_CR75","first-page":"2379","volume":"9","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Ding J, Sun S, Liu H, Lu M, Wei X, et al. Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy. Am J Cancer Res. 2019;9(11):2379\u201396.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"8299_CR76","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ijc.32201","volume":"145","author":"S Stock","year":"2019","unstructured":"Stock S, \u00dcbelhart R, Schubert M, Fan F, He B, Hoffmann J, et al. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients. Intl J Cancer. 2019;145(5):1312\u201324. https:\/\/doi.org\/10.1002\/ijc.32201.","journal-title":"Intl J Cancer"},{"issue":"4","key":"8299_CR77","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2021011597","volume":"139","author":"CR Funk","year":"2022","unstructured":"Funk CR, Wang S, Chen KZ, Waller A, Sharma A, Edgar CL, et al. PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood. 2022;139(4):523\u201337. https:\/\/doi.org\/10.1182\/blood.2021011597.","journal-title":"Blood"},{"issue":"21","key":"8299_CR78","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","volume":"27","author":"Z Nian","year":"2021","unstructured":"Nian Z, Zheng X, Dou Y, Du X, Zhou L, Fu B, et al. Rapamycin pretreatment rescues the bone Marrow AML cell elimination capacity of CAR-T cells. Clin Cancer Res. 2021;27(21):6026\u201338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0452.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8299_CR79","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","volume":"7","author":"J Liu","year":"2022","unstructured":"Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Sig Transduct Target Ther. 2022;7(1):3. https:\/\/doi.org\/10.1038\/s41392-021-00762-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8299_CR80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P Song","year":"2024","unstructured":"Song P, Gao Z, Bao Y, Chen L, Huang Y, Liu Y, et al. Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol. 2024;17(1):46. https:\/\/doi.org\/10.1186\/s13045-024-01563-4.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"8299_CR81","doi-asserted-by":"publisher","first-page":"114065","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"M Zhu","year":"2024","unstructured":"Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43(4):114065. https:\/\/doi.org\/10.1016\/j.celrep.2024.114065.","journal-title":"Cell Rep"},{"issue":"1","key":"8299_CR82","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12967-024-05907-z","volume":"23","author":"S Wu","year":"2025","unstructured":"Wu S, Wei Y, Qiu Y, Ai K, Chen M, Wang H, et al. Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt\/\u03b2-catenin pathway. J Transl Med. 2025;23(1):494. https:\/\/doi.org\/10.1186\/s12967-024-05907-z.","journal-title":"J Transl Med"},{"issue":"3","key":"8299_CR83","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11(3):599\u2013613. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0756.","journal-title":"Cancer Discov"},{"issue":"9","key":"8299_CR84","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 2020;135(9):597\u2013609. https:\/\/doi.org\/10.1182\/blood.2019002121.","journal-title":"Blood"},{"key":"8299_CR85","doi-asserted-by":"publisher","unstructured":"Xia L, Zheng Z, Liu J, Chen Y, Ding J, Xia N, et al. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Trans Imm. 2020;9(5):e 1135. https:\/\/doi.org\/10.1002\/cti2.1135.","DOI":"10.1002\/cti2.1135"},{"issue":"10","key":"8299_CR86","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","volume":"6","author":"F Yi","year":"2025","unstructured":"Yi F, Cohen T, Zimmerman N, D\u00fcndar F, Zumbo P, Eltilib R, et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand\u2013FAS autoregulatory circuit. Nat Cancer. 2025;6(10):1638\u201355. https:\/\/doi.org\/10.1038\/s43018-025-01009-x.","journal-title":"Nat Cancer"},{"issue":"11","key":"8299_CR87","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1158\/2326-6066.CIR-22-0115","volume":"10","author":"P Bajgain","year":"2022","unstructured":"Bajgain P, Torres Chavez AG, Balasubramanian K, Fleckenstein L, Lulla P, Heslop HE, et al. Secreted Fas decoys enhance the antitumor activity of engineered and bystander T cells in Fas Ligand\u2013expressing solid tumors. Cancer Immunol Res. 2022;10(11):1370\u201385. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0115.","journal-title":"Cancer Immunol Res"},{"issue":"8086","key":"8299_CR88","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41586-025-09507-9","volume":"646","author":"P Datlinger","year":"2025","unstructured":"Datlinger P, Pankevich EV, Arnold CD, Pranckevicius N, Lin J, Romanovskaia D, et al. Systematic discovery of CRISPR-boosted CAR T cell immunotherapies. Nature. 2025;646(8086):963\u201372. https:\/\/doi.org\/10.1038\/s41586-025-09507-9.","journal-title":"Nature"},{"key":"8299_CR89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jconrel.2020.07.013","volume":"326","author":"B Thapa","year":"2020","unstructured":"Thapa B, Kc R, Uluda\u011f H. TRAIL therapy and prospective developments for cancer treatment. J Control Release. 2020;326:335\u201349. https:\/\/doi.org\/10.1016\/j.jconrel.2020.07.013.","journal-title":"J Control Release"},{"issue":"4","key":"8299_CR90","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.bbrc.2014.10.024","volume":"453","author":"E Kobayashi","year":"2014","unstructured":"Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Bioph Res Co. 2014;453(4):798\u2013803. https:\/\/doi.org\/10.1016\/j.bbrc.2014.10.024.","journal-title":"Biochem Bioph Res Co"},{"issue":"1","key":"8299_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/cells13010101","volume":"13","author":"A Czaplicka","year":"2024","unstructured":"Czaplicka A, Lachota M, P\u0105czek L, Zago\u017cd\u017con R, Kaleta B. Chimeric antigen receptor T cell therapy for pancreatic Cancer: a review of Current evidence. Cells. 2024;13(1):13. https:\/\/doi.org\/10.3390\/cells13010101.","journal-title":"Cells"},{"issue":"43","key":"8299_CR92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1126\/sciimmunol.aax7969","volume":"5","author":"Y Liu","year":"2020","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43):5. https:\/\/doi.org\/10.1126\/sciimmunol.aax7969.","journal-title":"Sci Immunol"},{"issue":"7","key":"8299_CR93","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s43018-023-00570-7","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Guerin MV, Garcia Z, Alonso R, et al. Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity. Nat Cancer. 2023;4(7):968\u201383. https:\/\/doi.org\/10.1038\/s43018-023-00570-7.","journal-title":"Nat Cancer"},{"key":"8299_CR94","doi-asserted-by":"publisher","unstructured":"Bailey SR, Takei HN, Escobar G, Kann MC, Bouffard AA, Kienka T, et al. IFN-\u03b3\u2013resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models. Sci Transl Med. 2025;17(801):eadp 8166. https:\/\/doi.org\/10.1126\/scitranslmed.adp8166.","DOI":"10.1126\/scitranslmed.adp8166"},{"issue":"4","key":"8299_CR95","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"8299_CR96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-024-01528-7","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Chen S, He X, Yuan Y, Wei X. Targeting inflammation as cancer therapy. J Hematol Oncol. 2024;17(1):13. https:\/\/doi.org\/10.1186\/s13045-024-01528-7.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"8299_CR97","doi-asserted-by":"publisher","first-page":"101161","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 2023;4(9):101161. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101161.","journal-title":"Cell Rep. Med"},{"issue":"6","key":"8299_CR98","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731\u201338. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"issue":"6","key":"8299_CR99","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"issue":"21","key":"8299_CR100","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/cells12212581","volume":"12","author":"A Dibas","year":"2023","unstructured":"Dibas A, Rhiel M, Patel VB, Andrieux G, Boerries M, Cornu TI, et al. Cell-based models of \u2018Cytokine release syndrome\u2019 endorse CD40L and Granulocyte\u2013macrophage Colony-Stimulating factor knockout in chimeric antigen receptor T cells as mitigation strategy. Cells. 2023;12(21):12. https:\/\/doi.org\/10.3390\/cells12212581.","journal-title":"Cells"},{"issue":"7735","key":"8299_CR101","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-018-0774-y","volume":"564","author":"V Staedtke","year":"2018","unstructured":"Staedtke V, Bai R, Kim K, Darvas M, Davila ML, Riggins GJ, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature. 2018;564(7735):273\u201377. https:\/\/doi.org\/10.1038\/s41586-018-0774-y.","journal-title":"Nature"},{"key":"8299_CR102","doi-asserted-by":"publisher","unstructured":"Guo H, Li R, Wang M, Hou Y, Liu S, Peng T, et al. Multiomics analysis identifies SOCS1 as restraining T cell activation and Preventing graft-versus-host disease. Adv Sci. 2022;9(21):e2200978. https:\/\/doi.org\/10.1002\/advs.202200978.","DOI":"10.1002\/advs.202200978"},{"key":"8299_CR103","doi-asserted-by":"publisher","first-page":"109130","DOI":"10.1016\/j.intimp.2022.109130","volume":"111","author":"M Aliyu","year":"2022","unstructured":"Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, et al. Interleukin-6 cytokine: an overview of the immune regulation, immune dysregulation, and therapeutic approach. Int Immunopharmacol. 2022;111:109130. https:\/\/doi.org\/10.1016\/j.intimp.2022.109130.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"8299_CR104","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41375-020-01085-1","volume":"35","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Liao R, Lv J, Li S, Zheng D, Qin L, et al. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia. 2021;35(5):1380\u201391. https:\/\/doi.org\/10.1038\/s41375-020-01085-1.","journal-title":"Leukemia"},{"issue":"2","key":"8299_CR105","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"8299_CR106","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00277-025-06467-y","volume":"104","author":"X Wang","year":"2025","unstructured":"Wang X, He X, Zhang T, Liu J, Zhao M. Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies. Ann Hematol. 2025;104(6):3129\u201351. https:\/\/doi.org\/10.1007\/s00277-025-06467-y.","journal-title":"Ann Hematol"},{"issue":"2","key":"8299_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7.","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"8299_CR108","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.chembiol.2023.10.024","volume":"31","author":"IC Lane","year":"2024","unstructured":"Lane IC, Kembuan G, Carreiro J, Kann MC, Lin W, Bouffard AA, et al. Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell Chem Biol. 2024;31(2):338\u201348.e5. https:\/\/doi.org\/10.1016\/j.chembiol.2023.10.024.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"8299_CR109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41421-023-00528-0","volume":"9","author":"H Tian","year":"2023","unstructured":"Tian H, Liu C, Yu J, Han J, Du J, Liang S, et al. PHF14 enhances DNA methylation of SMAD7 gene to promote TGF-\u03b2-driven lung adenocarcinoma metastasis. Cell Discov. 2023;9(1):41. https:\/\/doi.org\/10.1038\/s41421-023-00528-0.","journal-title":"Cell Discov"},{"issue":"1","key":"8299_CR110","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-\u03b2 signaling in health, disease and therapeutics. Sig Transduct Target Ther. 2024;9(1):61. https:\/\/doi.org\/10.1038\/s41392-024-01764-w.","journal-title":"Sig Transduct Target Ther"},{"key":"8299_CR111","doi-asserted-by":"publisher","first-page":"157090","DOI":"10.1016\/j.cyto.2025.157090","volume":"198","author":"H Zhao","year":"2026","unstructured":"Zhao H, Yang F, Yang J, Yang S. SMAD signaling in cancer: integrative roles in tumor progression, immune evasion, and therapeutic resistance. Cytokine. 2026;198:157090. https:\/\/doi.org\/10.1016\/j.cyto.2025.157090.","journal-title":"Cytokine"},{"key":"8299_CR112","doi-asserted-by":"publisher","unstructured":"Wan R, Fu B, Fu X, Liu Z, Simayi N, Fu Y, et al. SMAD4 regulates the expression of LCK affecting chimeric antigen receptor-T cells proliferation through PI3K\/Akt signaling pathway. J Cellular Physiol. 2025;240(1):e31520. https:\/\/doi.org\/10.1002\/jcp.31520.","DOI":"10.1002\/jcp.31520"},{"key":"8299_CR113","doi-asserted-by":"publisher","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977. https:\/\/doi.org\/10.1172\/jci.insight.133977.","DOI":"10.1172\/jci.insight.133977"},{"issue":"9","key":"8299_CR114","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356. https:\/\/doi.org\/10.1038\/nbt.4195.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"8299_CR115","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388\u2013407.e9. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001.","journal-title":"Immunity"},{"issue":"1","key":"8299_CR116","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41392-020-00277-6","volume":"5","author":"F Li","year":"2020","unstructured":"Li F, Zhang Z, Xuan Y, Zhang D, Liu J, Li A, et al. PD-1 abrogates the prolonged persistence of CD8+ CAR-T cells with 4-1BB co-stimulation. Sig Transduct Target Ther. 2020;5(1):164. https:\/\/doi.org\/10.1038\/s41392-020-00277-6.","journal-title":"Sig Transduct Target Ther"},{"issue":"8","key":"8299_CR117","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy\u2014current perspectives and future directions. Cell. 2023;186(8):1652\u201369. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006.","journal-title":"Cell"},{"issue":"9","key":"8299_CR118","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322. https:\/\/doi.org\/10.1038\/s41590-023-01569-z.","journal-title":"Nat Immunol"},{"key":"8299_CR119","doi-asserted-by":"publisher","unstructured":"Leitner J, Aigner-Radakovics K, Steinberger P. LAG -3\u2014an incompletely understood target in cancer therapy. FASEB J. 2024;38(22):e70190. https:\/\/doi.org\/10.1096\/fj.202401639R.","DOI":"10.1096\/fj.202401639R"},{"issue":"10","key":"8299_CR120","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41551-025-01492-8","volume":"9","author":"TT Nguyen","year":"2025","unstructured":"Nguyen TT, Ho P, Staudt S, Gregoire C, Ziegler-Martin K, Jassin M, et al. Fine tuning towards the next generation of engineered T cells. Nat Biomed Eng. 2025;9(10):1610\u201331. https:\/\/doi.org\/10.1038\/s41551-025-01492-8.","journal-title":"Nat Biomed Eng"},{"issue":"2","key":"8299_CR121","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"J Chauvin","year":"2020","unstructured":"Chauvin J, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):8. https:\/\/doi.org\/10.1136\/jitc-2020-000957.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8299_CR122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","volume":"21","author":"VC Jiang","year":"2022","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, et al. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer. 2022;21(1):185. https:\/\/doi.org\/10.1186\/s12943-022-01655-0.","journal-title":"Mol Cancer"},{"issue":"7","key":"8299_CR123","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cac2.12452","volume":"43","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chen J, Wang X, Yan S, Tan J, Xia B, et al. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Commun (Lond). 2023;43(7):788\u2013807. https:\/\/doi.org\/10.1002\/cac2.12452.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"8299_CR124","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","volume":"16","author":"H Cui","year":"2025","unstructured":"Cui H, Hamad M, Elkord E. TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. Cell Death Dis. 2025;16(1):664. https:\/\/doi.org\/10.1038\/s41419-025-07984-4.","journal-title":"Cell Death Dis"},{"issue":"2","key":"8299_CR125","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010.","journal-title":"Immunity"},{"key":"8299_CR126","doi-asserted-by":"publisher","first-page":"845499","DOI":"10.3389\/fimmu.2022.845499","volume":"13","author":"F Blaeschke","year":"2022","unstructured":"Blaeschke F, Ortner E, Stenger D, Mahdawi J, Apfelbeck A, Habjan N, et al. Design and evaluation of TIM-3-CD28 checkpoint fusion proteins to improve anti-CD19 CAR T-Cell function. Front Immunol. 2022;13:845499. https:\/\/doi.org\/10.3389\/fimmu.2022.845499.","journal-title":"Front Immunol"},{"key":"8299_CR127","doi-asserted-by":"publisher","unstructured":"Ma S, Tian Y, Peng J, Chen C, Peng X, Zhao F, et al. Identification of a small-molecule tim-3 inhibitor to potentiate T cell\u2013mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg 6752. https:\/\/doi.org\/10.1126\/scitranslmed.adg6752.","DOI":"10.1126\/scitranslmed.adg6752"},{"issue":"1","key":"8299_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-023-01894-9","volume":"22","author":"F Ramezani","year":"2023","unstructured":"Ramezani F, Panahi Meymandi AR, Akbari B, Tamtaji OR, Mirzaei H, Brown CE, et al. Outsmarting trogocytosis to boost CAR NK\/T cell therapy. Mol Cancer. 2023;22(1):183. https:\/\/doi.org\/10.1186\/s12943-023-01894-9.","journal-title":"Mol Cancer"},{"issue":"7750","key":"8299_CR129","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112\u201316. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"issue":"1","key":"8299_CR130","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41392-023-01708-w","volume":"8","author":"Y Zhai","year":"2023","unstructured":"Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C, et al. Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape. Sig Transduct Target Ther. 2023;8(1):457. https:\/\/doi.org\/10.1038\/s41392-023-01708-w.","journal-title":"Sig Transduct Target Ther"},{"issue":"11","key":"8299_CR131","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep. Med. 2025;6(11):102353. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353.","journal-title":"Cell Rep. Med"},{"issue":"8046","key":"8299_CR132","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637(8046):708\u201315. https:\/\/doi.org\/10.1038\/s41586-024-08171-9.","journal-title":"Nature"},{"key":"8299_CR133","doi-asserted-by":"publisher","first-page":"1615526","DOI":"10.3389\/fphar.2025.1615526","volume":"16","author":"DF Driscoll","year":"2025","unstructured":"Driscoll DF, Bistrian BR. Cytokine release syndrome and CAR T cell therapy: modulating the intensity of the inflammatory response and resolution within the tumor microenvironment. Front Pharmacol. 2025;16:1615526. https:\/\/doi.org\/10.3389\/fphar.2025.1615526.","journal-title":"Front Pharmacol"},{"issue":"7","key":"8299_CR134","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217.","journal-title":"Nat Rev Clin Oncol"},{"key":"8299_CR135","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L. Shaping polarization of tumor-associated macrophages in Cancer immunotherapy. Front Immunol. 2022;13:888713. https:\/\/doi.org\/10.3389\/fimmu.2022.888713.","journal-title":"Front Immunol"},{"issue":"1","key":"8299_CR136","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1172\/JCI194631","volume":"136","author":"P Goala","year":"2026","unstructured":"Goala P, Zhang Y, Beatty N, Pavy A, McSain S, Sailer C, et al. IFN-\u03b3\u2013driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. J Clin Investigation. 2026;136(1):136. https:\/\/doi.org\/10.1172\/JCI194631.","journal-title":"J Clin Investigation"},{"issue":"17","key":"8299_CR137","doi-asserted-by":"publisher","first-page":"11165","DOI":"10.1021\/acsnano.4c00050","volume":"18","author":"N Zhu","year":"2024","unstructured":"Zhu N, Chen S, Jin Y, Wang M, Fang L, Xue L, et al. Enhancing glioblastoma immunotherapy with integrated chimeric antigen receptor T cells through the Re-education of tumor-associated microglia and macrophages. ACS Nano. 2024;18(17):11165\u201382. https:\/\/doi.org\/10.1021\/acsnano.4c00050.","journal-title":"ACS Nano"},{"issue":"1","key":"8299_CR138","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41419-025-07610-3","volume":"16","author":"L Zhao","year":"2025","unstructured":"Zhao L, Yan F, Tang D, Li W, An N, Ren C, et al. The transition between M1 and M2 macrophage phenotypes is associated with the disease status following CD19 CAR-T therapy for B cell lymphoma\/leukemia. Cell Death Dis. 2025;16(1):275. https:\/\/doi.org\/10.1038\/s41419-025-07610-3.","journal-title":"Cell Death Dis"},{"key":"8299_CR139","doi-asserted-by":"publisher","unstructured":"Hadjigeorgiou AG, Munn LL, Stylianopoulos T, Jain RK. Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors. Proc Natl Acad Sci USA. 2025;122(46):e1772333174. https:\/\/doi.org\/10.1073\/pnas.2522634122.","DOI":"10.1073\/pnas.2522634122"},{"issue":"5","key":"8299_CR140","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023;33(5):341\u201354. https:\/\/doi.org\/10.1038\/s41422-023-00789-0.","journal-title":"Cell Res"},{"issue":"2","key":"8299_CR141","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","volume":"30","author":"SR Zanetti","year":"2022","unstructured":"Zanetti SR, Velasco-Hernandez T, Gutierrez-Ag\u00fcera F, D\u00edaz VM, Romec\u00edn PA, Roca-Ho H, et al. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Mol Ther. 2022;30(2):550\u201363. https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.033.","journal-title":"Mol Ther"},{"issue":"2","key":"8299_CR142","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1182\/blood.2023020621","volume":"143","author":"S Ghorashian","year":"2024","unstructured":"Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, et al. CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL. Blood. 2024;143(2):118\u201323. https:\/\/doi.org\/10.1182\/blood.2023020621.","journal-title":"Blood"},{"key":"8299_CR143","doi-asserted-by":"publisher","unstructured":"Ash SL, Orha R, Mole H, Dinesh-Kumar M, Lee SP, Turrell FK, et al. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis. J Immunother Cancer. 2024;12(2):e 8608. https:\/\/doi.org\/10.1136\/jitc-2023-008608.","DOI":"10.1136\/jitc-2023-008608"},{"issue":"2","key":"8299_CR144","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021;218(2):218. https:\/\/doi.org\/10.1084\/jem.20192203.","journal-title":"J Exp Med"},{"issue":"8047","key":"8299_CR145","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637(8047):940\u201346. https:\/\/doi.org\/10.1038\/s41586-024-08261-8.","journal-title":"Nature"},{"key":"8299_CR146","doi-asserted-by":"publisher","unstructured":"Prinzing B, Schreiner P, Bell M, Fan Y, Krenciute G, Gottschalk S. MyD88\/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight. 2020;5(21):e136093. https:\/\/doi.org\/10.1172\/jci.insight.136093.","DOI":"10.1172\/jci.insight.136093"},{"key":"8299_CR147","doi-asserted-by":"crossref","unstructured":"Maynard LH, Cavanaugh EJ, Zhu H, Starke CE, Doherty SM, Einhaus TK, et al. Pooled CAR-T screening in nonhuman primates identifies designs with enhanced proliferation, trafficking, and persistence. Blood J. 2025;2025028683.","DOI":"10.1101\/2025.03.05.640197"},{"key":"8299_CR148","doi-asserted-by":"publisher","unstructured":"Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells. Sci Transl Med. 2019;11(499):eaau 5907. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907.","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"8299_CR149","doi-asserted-by":"publisher","unstructured":"Balagopalan L, Moreno T, Qin H, Angeles BC, Kondo T, Yi J, et al. Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs. Sci Signal. 2024;17(846):eadp 8569. https:\/\/doi.org\/10.1126\/scisignal.adp8569.","DOI":"10.1126\/scisignal.adp8569"},{"issue":"1","key":"8299_CR150","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-024-01986-y","volume":"9","author":"X Wang","year":"2024","unstructured":"Wang X, Tao X, Chen P, Jiang P, Li W, Chang H, et al. MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB. Sig Transduct Target Ther. 2024;9(1):293. https:\/\/doi.org\/10.1038\/s41392-024-01986-y.","journal-title":"Sig Transduct Target Ther"},{"issue":"5","key":"8299_CR151","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2023-008659","volume":"12","author":"T Gargett","year":"2024","unstructured":"Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. J Immunother Cancer. 2024;12(5):12. https:\/\/doi.org\/10.1136\/jitc-2023-008659.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"8299_CR152","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo H, Gonz\u00e1lez-Avalos E, Zhang W, Ramchandani P, Yang C, Lio C-WJ, et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol. 2021;22(8):983\u201395. https:\/\/doi.org\/10.1038\/s41590-021-00964-8.","journal-title":"Nat Immunol"},{"issue":"1","key":"8299_CR153","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66. https:\/\/doi.org\/10.1186\/s40164-024-00535-1.","journal-title":"Exp Hematol Oncol"},{"key":"8299_CR154","doi-asserted-by":"publisher","unstructured":"Wang MR, Mu W, Zhen A, Kitchen SG. CRISPR\/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming. Trends Biotechnol. 2026. https:\/\/doi.org\/10.1016\/j.tibtech.2025.12.001.","DOI":"10.1016\/j.tibtech.2025.12.001"},{"issue":"1","key":"8299_CR155","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jitc-2024-010540","volume":"13","author":"W Hu","year":"2025","unstructured":"Hu W, Li F, Liang Y, Liu S, Wang S, Shen C, et al. Glut3 overexpression improves environmental glucose uptake and antitumor efficacy of CAR-T cells in solid tumors. J Immunother Cancer. 2025;13(1):13. https:\/\/doi.org\/10.1136\/jitc-2024-010540.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"8299_CR156","doi-asserted-by":"publisher","first-page":"8658","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15(1):8658. https:\/\/doi.org\/10.1038\/s41467-024-52666-y.","journal-title":"Nat Commun"},{"issue":"7","key":"8299_CR157","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi Y, Kotchetkov IS, Dobrin A, Hanina SA, Rajasekhar VK, Healey JH, et al. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther. 2024;32(7):2393\u2013405. https:\/\/doi.org\/10.1016\/j.ymthe.2024.05.006.","journal-title":"Mol Ther"},{"issue":"9","key":"8299_CR158","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1038\/s41401-024-01287-8","volume":"45","author":"R Sun","year":"2024","unstructured":"Sun R, Liu Y, Sun Y, Zhou M, Wang Y, Shi B, et al. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma. Acta Pharmacol Sin. 2024;45(9):1937\u201350. https:\/\/doi.org\/10.1038\/s41401-024-01287-8.","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"8299_CR159","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2025.02.004","volume":"43","author":"T Schild","year":"2025","unstructured":"Schild T, Wallisch P, Zhao Y, Wang Y, Haughton L, Chirayil R, et al. Metabolic engineering to facilitate anti-tumor immunity. Cancer Cell. 2025;43(3):552\u201362.e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.004.","journal-title":"Cancer Cell"},{"key":"8299_CR160","doi-asserted-by":"publisher","first-page":"101385","DOI":"10.1016\/j.mam.2025.101385","volume":"105","author":"J Xia","year":"2025","unstructured":"Xia J, Jin J, Dai S, Fan H, Chen K, Li J, et al. Mitophagy: a key regulator of radiotherapy resistance in the tumor immune microenvironment. Mol Aspects Med. 2025;105:101385. https:\/\/doi.org\/10.1016\/j.mam.2025.101385.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"8299_CR161","doi-asserted-by":"publisher","first-page":"101400","DOI":"10.1016\/j.xcrm.2024.101400","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep. Med. 2024;5(2):101400. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101400.","journal-title":"Cell Rep. Med"},{"issue":"6527","key":"8299_CR162","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.abb2683","volume":"371","author":"K Xu","year":"2021","unstructured":"Xu K, Yin N, Peng M, Stamatiades EG, Shyu A, Li P, et al. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science. 2021;371(6527):405\u201310. https:\/\/doi.org\/10.1126\/science.abb2683.","journal-title":"Science"},{"issue":"8010","key":"8299_CR163","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang Y, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310. https:\/\/doi.org\/10.1038\/s41586-024-07242-1.","journal-title":"Nature"},{"issue":"8010","key":"8299_CR164","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629(8010):211\u201318. https:\/\/doi.org\/10.1038\/s41586-024-07300-8.","journal-title":"Nature"},{"issue":"11","key":"8299_CR165","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/j.immuni.2022.09.014","volume":"55","author":"D Denk","year":"2022","unstructured":"Denk D, Petrocelli V, Conche C, Drachsler M, Ziegler PK, Braun A, et al. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity. 2022;55(11):2059\u201373.e8. https:\/\/doi.org\/10.1016\/j.immuni.2022.09.014.","journal-title":"Immunity"},{"issue":"3","key":"8299_CR166","doi-asserted-by":"publisher","first-page":"102021","DOI":"10.1016\/j.xcrm.2025.102021","volume":"6","author":"A Akhtar","year":"2025","unstructured":"Akhtar A, Shakir M, Ansari MS, Divya D, Faizan MI, Chauhan V, et al. Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin a increases persistence and long-term anti-tumor activity. Cell Rep. Med. 2025;6(3):102021. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102021.","journal-title":"Cell Rep. Med"},{"issue":"9","key":"8299_CR167","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.7150\/ijbs.110406","volume":"21","author":"J You","year":"2025","unstructured":"You J, Yang X, Zhao J, Chen H, Tang Y, Ouyang D, et al. Enhancing CAR-T cell metabolic fitness and memory phenotype for improved efficacy against hepatocellular carcinoma. Int J Biol Sci. 2025;21(9):4231\u201351. https:\/\/doi.org\/10.7150\/ijbs.110406.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"8299_CR168","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2026.02.004","volume":"189","author":"S Liu","year":"2026","unstructured":"Liu S, Guruprasad P, Ramasubramanian R, Madhu B, Paruzzo L, Han K, et al. \u03b2-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell. 2026;189(6):1701\u201316.e24. https:\/\/doi.org\/10.1016\/j.cell.2026.02.004.","journal-title":"Cell"},{"issue":"1","key":"8299_CR169","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","volume":"36","author":"X Si","year":"2024","unstructured":"Si X, Shao M, Teng X, Huang Y, Meng Y, Wu L, et al. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab. 2024;36(1):176\u201392.e10. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.010.","journal-title":"Cell Metab"},{"issue":"3","key":"8299_CR170","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos K, Wang Y, Joshi SK, Frisch AT, Watson MJ, Kumar A, et al. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023;11(3):11. https:\/\/doi.org\/10.1136\/jitc-2022-006522.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"8299_CR171","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s42255-024-00976-2","volume":"6","author":"SJ McPhedran","year":"2024","unstructured":"McPhedran SJ, Carleton GA, Lum JJ. Metabolic engineering for optimized CAR-T cell therapy. Nat Metab. 2024;6(3):396\u2013408. https:\/\/doi.org\/10.1038\/s42255-024-00976-2.","journal-title":"Nat Metab"},{"issue":"5","key":"8299_CR172","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2643-3230.BCD-24-0203","volume":"6","author":"M Uribe-Herranz","year":"2025","unstructured":"Uribe-Herranz M, Oliver-Cald\u00e9s A, Mart\u00ednez-Micaelo N, Espa\u00f1ol-Rego M, Val-Casals M, Mart\u00ednez-Soler R, et al. Microbiota shape metabolic and immune determinants of CAR-T therapy and correlate with outcomes in myeloma. Blood Cancer Discov. 2025;6(5):484\u2013504. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0203.","journal-title":"Blood Cancer Discov"},{"issue":"9","key":"8299_CR173","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/2159-8290.CD-24-1230","volume":"15","author":"L Marcos-Kovandzic","year":"2025","unstructured":"Marcos-Kovandzic L, Avagliano M, Ben Khelil M, Srikanthan J, Abdallah R, Petrocelli V, et al. Gut Microbiota modulation through Akkermansia spp. Supplementation increases CAR T-cell potency. Cancer Discov. 2025;15(9):1905\u201326. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1230.","journal-title":"Cancer Discov"},{"issue":"10","key":"8299_CR174","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2 -mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro-Oncology. 2024;26(10):1850\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noae126.","journal-title":"Neuro-Oncology"},{"issue":"22","key":"8299_CR175","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1172\/JCI169655","volume":"133","author":"P Zanvit","year":"2023","unstructured":"Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, et al. Antitumor activity of AZD0754, a dnTgf\u03b2rii-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Investigation. 2023;133(22):133. https:\/\/doi.org\/10.1172\/JCI169655.","journal-title":"J Clin Investigation"},{"issue":"10","key":"8299_CR176","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y, Logun MT, Zhang L, Yu S, et al. Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther. 2024;32(10):3522\u201338. https:\/\/doi.org\/10.1016\/j.ymthe.2024.07.020.","journal-title":"Mol Ther"},{"issue":"9","key":"8299_CR177","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cancers17091534","volume":"17","author":"Z Zhao","year":"2025","unstructured":"Zhao Z, Cutmore LC, Baleeiro RB, Hartlebury JJ, Brown N, Chard-Dunmall L, et al. The combination of oncolytic virus and antibody blockade of TGF-\u03b2 enhances the efficacy of \u03b1v\u03b26-targeting CAR T cells against pancreatic Cancer in an immunocompetent model. Cancers (Basel). 2025;17(9):17. https:\/\/doi.org\/10.3390\/cancers17091534.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"8299_CR178","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1182\/blood.2024025673","volume":"145","author":"SK Koh","year":"2025","unstructured":"Koh SK, Kim H, Han B, Jo H, Doh J, Park J, et al. Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T\/-NK cells and reduces trogocytosis. Blood. 2025;145(9):956\u201369. https:\/\/doi.org\/10.1182\/blood.2024025673.","journal-title":"Blood"},{"issue":"9","key":"8299_CR179","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cmet.2022.08.007","volume":"34","author":"Z Lu","year":"2022","unstructured":"Lu Z, McBrearty N, Chen J, Tomar VS, Zhang H, De Rosa G, et al. ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes. Cell Metab. 2022;34(9):1342\u201358.e7. https:\/\/doi.org\/10.1016\/j.cmet.2022.08.007.","journal-title":"Cell Metab"},{"issue":"7","key":"8299_CR180","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jitc-2024-011067","volume":"13","author":"T Nakashima","year":"2025","unstructured":"Nakashima T, Ouchida T, Ishikawa Y, Ito Y, Hayakawa T, Yoshikawa T, et al. JAK-STAT-activated, fratricide-resistant CAR-T cells targeting membrane-bound TNF effectively treat AML and solid tumors. J Immunother Cancer. 2025;13(7):13. https:\/\/doi.org\/10.1136\/jitc-2024-011067.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"8299_CR181","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh BLZ, Shimasaki N, Coustan-Smith E, Chan E, Poon L, Lee SHR, et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med. 2024;30(12):3687\u201396. https:\/\/doi.org\/10.1038\/s41591-024-03228-8.","journal-title":"Nat Med"},{"key":"8299_CR182","doi-asserted-by":"publisher","first-page":"816761","DOI":"10.3389\/fimmu.2022.816761","volume":"13","author":"W Luo","year":"2022","unstructured":"Luo W, Napoleon JV, Zhang F, Lee YG, Wang B, Putt KS, et al. Repolarization of tumor-infiltrating myeloid cells for augmentation of CAR T cell therapies. Front Immunol. 2022;13:816761. https:\/\/doi.org\/10.3389\/fimmu.2022.816761.","journal-title":"Front Immunol"},{"issue":"1","key":"8299_CR183","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O\u2019Connor RS, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12(1):877. https:\/\/doi.org\/10.1038\/s41467-021-20893-2.","journal-title":"Nat Commun"},{"issue":"7","key":"8299_CR184","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026\u201338. https:\/\/doi.org\/10.1182\/blood.2021012634.","journal-title":"Blood"},{"issue":"2","key":"8299_CR185","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, et al. Timing of anti\u2013PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2024;8(2):453\u201367. https:\/\/doi.org\/10.1182\/bloodadvances.2023011287.","journal-title":"Blood Adv"},{"issue":"3","key":"8299_CR186","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.omtn.2025.102618","volume":"36","author":"MS Roman Azcona","year":"2025","unstructured":"Roman Azcona MS, Monaco G, Whitehead M, Kaufmann MM, Alzubi J, Cathomen T, et al. Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing. Mol Ther Nucleic Acids. 2025;36(3):102618. https:\/\/doi.org\/10.1016\/j.omtn.2025.102618.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"22","key":"8299_CR187","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood.2024025440","volume":"145","author":"A Falg\u00e0s","year":"2025","unstructured":"Falg\u00e0s A, L\u00e1zaro-Gorines R, Zanetti SR, Rubio-P\u00e9rez L, Mart\u00ednez-Moreno A, Vinyoles M, et al. A TIM-3\u2013fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Blood. 2025;145(22):2599\u2013613. https:\/\/doi.org\/10.1182\/blood.2024025440.","journal-title":"Blood"},{"issue":"1","key":"8299_CR188","doi-asserted-by":"publisher","first-page":"2529632","DOI":"10.1080\/2162402X.2025.2529632","volume":"14","author":"A Oliver-Caldes","year":"2025","unstructured":"Oliver-Caldes A, Ma\u00f1e Pujol J, Battram AM, Perez-Amill L, Bachiller M, Calderon H, et al. TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model. Oncoimmunology. 2025;14(1):2529632. https:\/\/doi.org\/10.1080\/2162402X.2025.2529632.","journal-title":"Oncoimmunology"},{"issue":"2","key":"8299_CR189","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9(2):122\u201339. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003.","journal-title":"Trends Cancer"},{"key":"8299_CR190","doi-asserted-by":"publisher","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","volume":"15","author":"E Ponterio","year":"2024","unstructured":"Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors. Front Immunol. 2024;15:1455163. https:\/\/doi.org\/10.3389\/fimmu.2024.1455163.","journal-title":"Front Immunol"},{"issue":"1","key":"8299_CR191","doi-asserted-by":"publisher","first-page":"2612377","DOI":"10.1080\/2162402X.2025.2612377","volume":"15","author":"Y Tang","year":"2026","unstructured":"Tang Y, E Q, Ma L, Li X, Zhang Y, Wang W, et al. Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation. Oncoimmunology. 2026;15(1):2612377. https:\/\/doi.org\/10.1080\/2162402X.2025.2612377.","journal-title":"Oncoimmunology"},{"issue":"1","key":"8299_CR192","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","volume":"31","author":"G Wang","year":"2023","unstructured":"Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31(1):134\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.021.","journal-title":"Mol Ther"},{"issue":"1","key":"8299_CR193","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","volume":"11","author":"D Xiao","year":"2026","unstructured":"Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y. Oncolytic viruses: advanced strategies in cancer therapy. Sig Transduct Target Ther. 2026;11(1):45. https:\/\/doi.org\/10.1038\/s41392-025-02343-3.","journal-title":"Sig Transduct Target Ther"},{"issue":"2","key":"8299_CR194","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1039\/D4BM01305K","volume":"13","author":"G Huang","year":"2025","unstructured":"Huang G, He Y, Chen X, Yin T, Ma A, Zhu L, et al. Bioorthogonal oncolytic-virus nanovesicles combined bio-immunotherapy with CAR-T cells for solid tumors. Biomater Sci. 2025;13(2):457\u201365. https:\/\/doi.org\/10.1039\/D4BM01305K.","journal-title":"Biomater Sci"},{"issue":"6","key":"8299_CR195","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","volume":"43","author":"T Rakhshandehroo","year":"2025","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, Munaretto L, et al. A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2025;43(6):948\u201359. https:\/\/doi.org\/10.1038\/s41587-024-02339-4.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"8299_CR196","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. https:\/\/doi.org\/10.1038\/s41467-020-20599-x.","journal-title":"Nat Commun"},{"issue":"1","key":"8299_CR197","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu L, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14(1):2041. https:\/\/doi.org\/10.1038\/s41467-023-37874-2.","journal-title":"Nat Commun"},{"key":"8299_CR198","doi-asserted-by":"publisher","first-page":"108763","DOI":"10.1016\/j.pharmthera.2024.108763","volume":"266","author":"K Misawa","year":"2025","unstructured":"Misawa K, Bhat H, Adusumilli PS, Hou Z. Combinational CAR T-cell therapy for solid tumors: requisites, rationales, and trials. Pharmacol Ther. 2025;266:108763. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108763.","journal-title":"Pharmacol Ther"},{"key":"8299_CR199","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","volume":"353","author":"IS Pinto","year":"2023","unstructured":"Pinto IS, Cordeiro RA, Faneca H. Polymer- and lipid-based gene delivery technology for CAR T cell therapy. J Control Release. 2023;353:196\u2013215. https:\/\/doi.org\/10.1016\/j.jconrel.2022.11.038.","journal-title":"J Control Release"},{"key":"8299_CR200","doi-asserted-by":"publisher","unstructured":"Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J Immunother Cancer. 2023;11(3):e 6292. https:\/\/doi.org\/10.1136\/jitc-2022-006292.","DOI":"10.1136\/jitc-2022-006292"},{"issue":"11","key":"8299_CR201","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","volume":"32","author":"Z Chen","year":"2024","unstructured":"Chen Z, Shu J, Hu Y, Mei H. Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy. Mol Ther. 2024;32(11):3772\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.019.","journal-title":"Mol Ther"},{"issue":"7","key":"8299_CR202","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jitc-2025-011759","volume":"13","author":"JF Bimbo","year":"2025","unstructured":"Bimbo JF, van Diest E, Murphy DE, Ashoti A, Evers M, Narayanavari SA, et al. T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles. J Immunother Cancer. 2025;13(7):13. https:\/\/doi.org\/10.1136\/jitc-2025-011759.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"8299_CR203","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1021\/acs.accounts.2c00770","volume":"56","author":"R Xiong","year":"2023","unstructured":"Xiong R, Sauvage F, Fraire JC, Huang C, De Smedt SC, Braeckmans K. Photothermal nanomaterial-mediated photoporation. Acc Chem Res. 2023;56(6):631\u201343. https:\/\/doi.org\/10.1021\/acs.accounts.2c00770.","journal-title":"Acc Chem Res"},{"key":"8299_CR204","doi-asserted-by":"publisher","unstructured":"Shokouhi AR, Chen Y, Yoh HZ, Brenker J, Alan T, Murayama T, et al. Engineering efficient CAR-T cells via Electroactive nanoinjection. Adv Mater. 2023;35(44):e2304122. https:\/\/doi.org\/10.1002\/adma.202304122.","DOI":"10.1002\/adma.202304122"},{"key":"8299_CR205","doi-asserted-by":"publisher","unstructured":"Abdulla A, Abudureheman T, Chen K, Ghalandari B, Yan H, Zhou H, et al. Efficient capture and traceless release of functional CD8 + T cells with a microfluidic chip for enhanced in vitro and in vivo CD4-CAR transduction. Anal Chem. 2024. https:\/\/doi.org\/10.1021\/acs.analchem.4c03135.","DOI":"10.1021\/acs.analchem.4c03135"},{"issue":"26","key":"8299_CR206","doi-asserted-by":"publisher","first-page":"10780","DOI":"10.1021\/acs.analchem.4c01981","volume":"96","author":"H Jeon","year":"2024","unstructured":"Jeon H, Perez CR, Kyung T, Birnbaum ME, Han J. Separation of activated T cells using multidimensional Double spiral (MDDS) inertial microfluidics for high-efficiency CAR T cell manufacturing. Anal Chem. 2024;96(26):10780\u201390. https:\/\/doi.org\/10.1021\/acs.analchem.4c01981.","journal-title":"Anal Chem"},{"key":"8299_CR207","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.eng.2024.11.030","volume":"47","author":"Z Li","year":"2025","unstructured":"Li Z, Tian Z, Belling JN, Rich JT, Zhu H, Ma Z, et al. Acoustofluidics-based intracellular Nanoparticle delivery. Eng (Beijing). 2025;47:130\u201338. https:\/\/doi.org\/10.1016\/j.eng.2024.11.030.","journal-title":"Eng (Beijing)"},{"issue":"9","key":"8299_CR208","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314. https:\/\/doi.org\/10.1038\/s41591-019-0549-5.","journal-title":"Nat Med"},{"issue":"7","key":"8299_CR209","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jcyt.2022.03.008","volume":"24","author":"ML Giardino Torchia","year":"2022","unstructured":"Giardino Torchia ML, Gilbreth R, Merlino A, Sult E, Monks N, Chesebrough J, et al. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. Cytotherapy. 2022;24(7):720\u201332. https:\/\/doi.org\/10.1016\/j.jcyt.2022.03.008.","journal-title":"Cytotherapy"},{"issue":"3","key":"8299_CR210","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.7150\/thno.66832","volume":"12","author":"D Li","year":"2022","unstructured":"Li D, Wang W, Xie S, Ge M, Wang R, Xu Q, et al. A T-cell independent universal cellular therapy strategy through antigen depletion. Theranostics. 2022;12(3):1148\u201360. https:\/\/doi.org\/10.7150\/thno.66832.","journal-title":"Theranostics"},{"key":"8299_CR211","doi-asserted-by":"publisher","first-page":"724211","DOI":"10.3389\/fimmu.2021.724211","volume":"12","author":"A Zhang","year":"2021","unstructured":"Zhang A, Sun Y, Du J, Dong Y, Pang H, Ma L, et al. Reducing hinge flexibility of CAR-T cells prolongs survival in vivo with low cytokines release. Front Immunol. 2021;12:724211. https:\/\/doi.org\/10.3389\/fimmu.2021.724211.","journal-title":"Front Immunol"},{"issue":"1","key":"8299_CR212","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","volume":"10","author":"P Wang","year":"2025","unstructured":"Wang P, Wang Y, Zhao X, Zheng R, Zhang Y, Meng R, et al. Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Sig Transduct Target Ther. 2025;10(1):20. https:\/\/doi.org\/10.1038\/s41392-024-02096-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"10","key":"8299_CR213","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3390\/cancers15102767","volume":"15","author":"L Wu","year":"2023","unstructured":"Wu L, Chen J, Cai R, Wang X, Liu Y, Zheng Q, et al. Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-Cell therapy containing 4-1BB and CD28 Co-stimulatory domains for B-Cell acute lymphoblastic leukemia. Cancers (Basel). 2023;15(10):2767. https:\/\/doi.org\/10.3390\/cancers15102767.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"8299_CR214","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","volume":"36","author":"E Jacoby","year":"2022","unstructured":"Jacoby E, Ghorashian S, Vormoor B, De Moerloose B, Bodmer N, Molostova O, et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022;36(6):1525\u201332. https:\/\/doi.org\/10.1038\/s41375-022-01546-9.","journal-title":"Leukemia"},{"key":"8299_CR215","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.eclinm.2025.103267","volume":"84","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Liu K, Rosen ST, Liu W, Zhu H. Treatment-related adverse events of chimeric antigen receptor-T therapies for cancers in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2025;84:103267. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103267.","journal-title":"EClinicalMedicine"},{"key":"8299_CR216","doi-asserted-by":"publisher","unstructured":"Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, et al. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023;11(1):e 5878. https:\/\/doi.org\/10.1136\/jitc-2022-005878.","DOI":"10.1136\/jitc-2022-005878"},{"issue":"10254","key":"8299_CR217","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"6","key":"8299_CR218","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","volume":"5","author":"JS Abramson","year":"2021","unstructured":"Abramson JS, Siddiqi T, Garcia J, Dehner C, Kim Y, Nguyen A, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel\u2013treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695\u2013705. https:\/\/doi.org\/10.1182\/bloodadvances.2020003531.","journal-title":"Blood Adv"},{"issue":"6","key":"8299_CR219","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-019-0421-7","volume":"25","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019;25(6):947\u201353. https:\/\/doi.org\/10.1038\/s41591-019-0421-7.","journal-title":"Nat Med"},{"issue":"30","key":"8299_CR220","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in Adults with relapsed or refractory B-Cell acute lymphoblastic leukemia. JCO. 2021;39(30):3352\u201363. https:\/\/doi.org\/10.1200\/JCO.21.00917.","journal-title":"JCO"},{"issue":"9","key":"8299_CR221","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","volume":"50","author":"T Schroeder","year":"2024","unstructured":"Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, et al. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Intensive Care Med. 2024;50(9):1459\u201369. https:\/\/doi.org\/10.1007\/s00134-024-07576-4.","journal-title":"Intensive Care Med"},{"key":"8299_CR222","doi-asserted-by":"publisher","first-page":"1530623","DOI":"10.3389\/fimmu.2025.1530623","volume":"16","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, An Y, Zhang X, Xiao X, Bai X, Liu P, et al. Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Front Immunol. 2025;16:1530623. https:\/\/doi.org\/10.3389\/fimmu.2025.1530623.","journal-title":"Front Immunol"},{"issue":"1","key":"8299_CR223","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14(1):84. https:\/\/doi.org\/10.1038\/s41408-024-01048-0.","journal-title":"Blood Cancer J"},{"issue":"15","key":"8299_CR224","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1002\/cncr.35316","volume":"130","author":"X Wang","year":"2024","unstructured":"Wang X, Zhang B, Zhang Q, Zhou H, Sun Q, Zhou Y, et al. Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia. Cancer. 2024;130(15):2660\u201369. https:\/\/doi.org\/10.1002\/cncr.35316.","journal-title":"Cancer"},{"key":"8299_CR225","doi-asserted-by":"publisher","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for Non-Hodgkin Lymphoma. Front Immunol. 2021;12:745320. https:\/\/doi.org\/10.3389\/fimmu.2021.745320.","journal-title":"Front Immunol"},{"issue":"8","key":"8299_CR226","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist. 2018;23(8):943\u201347. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028.","journal-title":"The Oncologist"},{"key":"8299_CR227","doi-asserted-by":"publisher","unstructured":"Lin M, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, et al. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy. J Exp Med. 2024;221(6):e20221988. https:\/\/doi.org\/10.1084\/jem.20221988.","DOI":"10.1084\/jem.20221988"},{"issue":"1","key":"8299_CR228","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-025-00638-3","volume":"14","author":"V Gal\u00e1n-G\u00f3mez","year":"2025","unstructured":"Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, et al. Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol. 2025;14(1):49. https:\/\/doi.org\/10.1186\/s40164-025-00638-3.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"8299_CR229","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688","volume":"9","author":"A Bajwa","year":"2025","unstructured":"Bajwa A, Zhao Q, Geer M, Lin C, Westholder J, Maakaron J, et al. Siltuximab for chimeric antigen receptor T-cell therapy\u2013related CRS and ICANS: a multicenter retrospective analysis. Blood Adv. 2025;9(1):170\u201375. https:\/\/doi.org\/10.1182\/bloodadvances.2024013688.","journal-title":"Blood Adv"},{"key":"8299_CR230","doi-asserted-by":"publisher","first-page":"1219289","DOI":"10.3389\/fimmu.2023.1219289","volume":"14","author":"M Caballero-Bell\u00f3n","year":"2023","unstructured":"Caballero-Bell\u00f3n M, Alonso-Saladrigues A, Bobillo-Perez S, Faura A, Arqu\u00e9s L, Rivera C, et al. Risk factors and outcome of chimeric antigen receptor T-Cell patients admitted to pediatric Intensive care unit: CART-PICU study. Front Immunol. 2023;14:1219289. https:\/\/doi.org\/10.3389\/fimmu.2023.1219289.","journal-title":"Front Immunol"},{"key":"8299_CR231","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"J Zhou","year":"2022","unstructured":"Zhou J, Sun L, Jia Y, Wang Z, Luo T, Tan J, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"issue":"1","key":"8299_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.2016005","volume":"18","author":"H Zhang","year":"2022","unstructured":"Zhang H, Lv X, Kong Q, Tan Y. IL-6\/IFN-\u03b3 double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Hum Vaccines Immunotherapeutics. 2022;18(1):1\u201314. https:\/\/doi.org\/10.1080\/21645515.2021.2016005.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"8299_CR233","doi-asserted-by":"publisher","unstructured":"Ma JF, Yan JW, Liu MJ, Yan CL, Tang XW, Qiu HY, et al. Safe and potent anti-CD19 CAR T-cells with shRNA-IL-6 gene silencing element in patients with refractory or relapsed B-cell acute lymphoblastic leukemia. Hemasphere. 2024;8(10):e70007. https:\/\/doi.org\/10.1002\/hem3.70007.","DOI":"10.1002\/hem3.70007"},{"issue":"11","key":"8299_CR234","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1084\/jem.20230577","volume":"220","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang Y, Xing X, Xu G, Lin X, Wang Y, et al. IL-6 translation is a therapeutic target of human cytokine release syndrome. J Exp Med. 2023;220(11):220. https:\/\/doi.org\/10.1084\/jem.20230577.","journal-title":"J Exp Med"},{"issue":"5","key":"8299_CR235","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","volume":"45","author":"B Becher","year":"2016","unstructured":"Becher B, Tugues S, Greter M. GM-CSF: from growth Factor to central mediator of tissue inflammation. Immunity. 2016;45(5):963\u201373. https:\/\/doi.org\/10.1016\/j.immuni.2016.10.026.","journal-title":"Immunity"},{"issue":"1","key":"8299_CR236","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9(1):15. https:\/\/doi.org\/10.1186\/s40164-020-00171-5.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"8299_CR237","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697\u2013709. https:\/\/doi.org\/10.1182\/blood-2018-10-881722.","journal-title":"Blood"},{"issue":"1","key":"8299_CR238","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","volume":"14","author":"S Manni","year":"2023","unstructured":"Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, et al. Neutralizing IFN\u03b3 improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023;14(1):3423. https:\/\/doi.org\/10.1038\/s41467-023-38723-y.","journal-title":"Nat Commun"},{"issue":"2","key":"8299_CR239","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","volume":"3","author":"SR Bailey","year":"2022","unstructured":"Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarf\u00f2 I, Kann MC, et al. Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov. 2022;3(2):136\u201353. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0181.","journal-title":"Blood Cancer Discov"},{"key":"8299_CR240","doi-asserted-by":"publisher","first-page":"1543622","DOI":"10.3389\/fonc.2025.1543622","volume":"15","author":"T Ruemmele","year":"2025","unstructured":"Ruemmele T, Macedo R, Stein MN, Chan HT, Mapara MY, Jacquemont CF, et al. Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report. Front Oncol. 2025;15:1543622. https:\/\/doi.org\/10.3389\/fonc.2025.1543622.","journal-title":"Front Oncol"},{"issue":"2","key":"8299_CR241","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3892\/ol.2024.14817","volume":"29","author":"W Cai","year":"2024","unstructured":"Cai W, Lu Y, He H, Li J, Liu S, Geng H, et al. Efficacy of emapalumab in the management of anti\u2011CD19 chimeric antigen receptor T\u2011cell therapy\u2011associated cytokine release syndrome: a report of two cases. Oncol Lett. 2024;29(2):71. https:\/\/doi.org\/10.3892\/ol.2024.14817.","journal-title":"Oncol Lett"},{"key":"8299_CR242","doi-asserted-by":"publisher","first-page":"1563736","DOI":"10.3389\/fimmu.2025.1563736","volume":"16","author":"B Manghisi","year":"2025","unstructured":"Manghisi B, Cotilli G, Fedele M, Perfetti P, Terruzzi E, Verga L, et al. Case report: successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. Front Immunol. 2025;16:1563736. https:\/\/doi.org\/10.3389\/fimmu.2025.1563736.","journal-title":"Front Immunol"},{"key":"8299_CR243","doi-asserted-by":"publisher","first-page":"623610","DOI":"10.3389\/fimmu.2021.623610","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li R, Shang S, Yang X, Li L, Wang W, et al. Therapeutic potential of TNF\u03b1 and IL1\u03b2 blockade for CRS\/ICANS in CAR-T therapy via ameliorating Endothelial activation. Front Immunol. 2021;12:623610. https:\/\/doi.org\/10.3389\/fimmu.2021.623610.","journal-title":"Front Immunol"},{"key":"8299_CR244","doi-asserted-by":"publisher","first-page":"2022017414","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood. 2023;141:2022017414. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"issue":"9","key":"8299_CR245","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","volume":"9","author":"MJ Frigault","year":"2025","unstructured":"Frigault MJ, Yao N, Berger TR, Wehrli M, Gallagher KME, Horick N, et al. Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv. 2025;9(9):2122\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2024015161.","journal-title":"Blood Adv"},{"issue":"8","key":"8299_CR246","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/eji.202149181","volume":"51","author":"L Nouveau","year":"2021","unstructured":"Nouveau L, Buatois V, Cons L, Chatel L, Pontini G, Pleche N, et al. Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies. Eur J Immunol. 2021;51(8):2074\u201385. https:\/\/doi.org\/10.1002\/eji.202149181.","journal-title":"Eur J Immunol"},{"issue":"1","key":"8299_CR247","doi-asserted-by":"publisher","first-page":"2083479","DOI":"10.1080\/2162402X.2022.2083479","volume":"11","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022;11(1):2083479. https:\/\/doi.org\/10.1080\/2162402X.2022.2083479.","journal-title":"Oncoimmunology"},{"issue":"23","key":"8299_CR248","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","volume":"26","author":"E Huarte","year":"2020","unstructured":"Huarte E, O\u2019Connor RS, Peel MT, Nunez-Cruz S, Leferovich J, Juvekar A, et al. Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy. Clin Cancer Res. 2020;26(23):6299\u2013309. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1739.","journal-title":"Clin Cancer Res"},{"key":"8299_CR249","doi-asserted-by":"publisher","unstructured":"Zi FM, Ye LL, Zheng JF, Cheng J, Wang QM. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia. Med (Baltim). 2021;100(19):e25786. https:\/\/doi.org\/10.1097\/MD.0000000000025786.","DOI":"10.1097\/MD.0000000000025786"},{"key":"8299_CR250","doi-asserted-by":"publisher","first-page":"156483","DOI":"10.1016\/j.phymed.2025.156483","volume":"139","author":"Y Wang","year":"2025","unstructured":"Wang Y, Ding L, Wang Y, Li H, Wu M, Li S, et al. Tetrandrine alleviates macrophage activation syndrome after CAR-T cell therapy. Phytomedicine. 2025;139:156483. https:\/\/doi.org\/10.1016\/j.phymed.2025.156483.","journal-title":"Phytomedicine"},{"issue":"21","key":"8299_CR251","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.3390\/cells12212581","volume":"12","author":"A Dibas","year":"2023","unstructured":"Dibas A, Rhiel M, Patel VB, Andrieux G, Boerries M, Cornu TI, et al. Cell-based models of \u2018Cytokine release syndrome\u2019 Endorse CD40L and Granulocyte\u2013macrophage Colony-Stimulating Factor knockout in chimeric antigen receptor T cells as mitigation strategy. Cells. 2023;12(21):2581. https:\/\/doi.org\/10.3390\/cells12212581.","journal-title":"Cells"},{"issue":"11","key":"8299_CR252","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41551-021-00781-2","volume":"5","author":"IC Miller","year":"2021","unstructured":"Miller IC, Zamat A, Sun L, Phuengkham H, Harris AM, Gamboa L, et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat Biomed Eng. 2021;5(11):1348\u201359. https:\/\/doi.org\/10.1038\/s41551-021-00781-2.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"8299_CR253","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-024-01648-0","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, An L, Wang X, Dai Y, Zhang C, Wen Q, et al. Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system. J Hematol Oncol. 2024;17(1):122. https:\/\/doi.org\/10.1186\/s13045-024-01648-0.","journal-title":"J Hematol Oncol"},{"issue":"14","key":"8299_CR254","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2210859.","journal-title":"N Engl J Med"},{"issue":"23","key":"8299_CR255","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1182\/blood.2021010784","volume":"137","author":"MC Foster","year":"2021","unstructured":"Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, et al. Utility of a safety switch to abrogate CD19.CAR T-cell\u2013associated neurotoxicity. Blood. 2021;137(23):3306\u201309. https:\/\/doi.org\/10.1182\/blood.2021010784.","journal-title":"Blood"},{"issue":"11","key":"8299_CR256","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"H Li","year":"2022","unstructured":"Li H, Wong NM, Tague E, Ngo JT, Khalil AS, Wong WW. High-performance multiplex drug-gated CAR circuits. Cancer Cell. 2022;40(11):1294\u2013305.e4. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.008.","journal-title":"Cancer Cell"},{"issue":"10","key":"8299_CR257","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;185(10):1745\u201363.e22. https:\/\/doi.org\/10.1016\/j.cell.2022.03.041.","journal-title":"Cell"},{"key":"8299_CR258","doi-asserted-by":"publisher","first-page":"1545270","DOI":"10.3389\/fimmu.2025.1545270","volume":"16","author":"M Shirzadian","year":"2025","unstructured":"Shirzadian M, Moori S, Rabbani R, Rahbarizadeh F. SynNotch CAR-T cell, when synthetic biology and immunology meet again. Front Immunol. 2025;16:1545270. https:\/\/doi.org\/10.3389\/fimmu.2025.1545270.","journal-title":"Front Immunol"},{"key":"8299_CR259","doi-asserted-by":"publisher","unstructured":"Reddy NR, Maachi H, Xiao Y, Simic MS, Yu W, Tonai Y, et al. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science. 2024;386(6726):eadl 4793. https:\/\/doi.org\/10.1126\/science.adl4793.","DOI":"10.1126\/science.adl4793"},{"issue":"1","key":"8299_CR260","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41392-025-02178-y","volume":"10","author":"J Nie","year":"2025","unstructured":"Nie J, Zhou L, Tian W, Liu X, Yang L, Yang X, et al. Deep insight into cytokine storm: from pathogenesis to treatment. Sig Transduct Target Ther. 2025;10(1):112. https:\/\/doi.org\/10.1038\/s41392-025-02178-y.","journal-title":"Sig Transduct Target Ther"},{"issue":"35","key":"8299_CR261","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO guideline. JCO. 2021;39(35):3978\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01992.","journal-title":"JCO"},{"key":"8299_CR262","doi-asserted-by":"publisher","unstructured":"Synnott D, O\u2019Reilly D, De Freitas D, Naidoo J. Cytokine release syndrome in solid tumors. Cancer. 2025;131(17):e70069. https:\/\/doi.org\/10.1002\/cncr.70069.","DOI":"10.1002\/cncr.70069"},{"issue":"23","key":"8299_CR263","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272\u201376. https:\/\/doi.org\/10.1182\/blood.2020008865.","journal-title":"Blood"},{"issue":"1","key":"8299_CR264","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12967-024-05063-4","volume":"22","author":"T Poiret","year":"2024","unstructured":"Poiret T, Vikberg S, Schoutrop E, Mattsson J, Magalhaes I. CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude. J Transl Med. 2024;22(1):273. https:\/\/doi.org\/10.1186\/s12967-024-05063-4.","journal-title":"J Transl Med"},{"key":"8299_CR265","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood. 2023;141:2430\u201342. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"key":"8299_CR266","doi-asserted-by":"publisher","first-page":"1597512","DOI":"10.3389\/fimmu.2025.1597512","volume":"16","author":"J Zhang","year":"2025","unstructured":"Zhang J, Xie D, Tang M, Gong Q, Huang X, Li J, et al. Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights. Front Immunol. 2025;16:1597512. https:\/\/doi.org\/10.3389\/fimmu.2025.1597512.","journal-title":"Front Immunol"},{"issue":"2","key":"8299_CR267","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jtct.2025.09.028","volume":"32","author":"KO McNerney","year":"2026","unstructured":"McNerney KO, Diorio C, Annesley C, Gardner RA, Graham AK, Sanchez-Pinto LN, et al. Management practices of CAR T-cell-related inflammatory toxicities: a survey of pediatric CAR T-cell providers. Transplant Cellular Ther. 2026;32(2):158\u201368. https:\/\/doi.org\/10.1016\/j.jtct.2025.09.028.","journal-title":"Transplant Cellular Ther"},{"issue":"16","key":"8299_CR268","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"5","key":"8299_CR269","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.xcrm.2024.101526","volume":"5","author":"T Yoshikawa","year":"2024","unstructured":"Yoshikawa T, Ito Y, Wu Z, Kasuya H, Nakashima T, Okamoto S, et al. Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. Cell Rep. Med. 2024;5(5):101526. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101526.","journal-title":"Cell Rep. Med"},{"issue":"21","key":"8299_CR270","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1158\/1078-0432.CCR-21-4384","volume":"28","author":"H Meister","year":"2022","unstructured":"Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin Cancer Res. 2022;28(21):4747\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4384.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8299_CR271","doi-asserted-by":"publisher","first-page":"2412371","DOI":"10.1080\/2162402X.2024.2412371","volume":"13","author":"C Pellegrino","year":"2024","unstructured":"Pellegrino C, Favalli N, Volta L, Benz R, Puglioli S, Bassi G, et al. Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors. Oncoimmunology. 2024;13(1):2412371. https:\/\/doi.org\/10.1080\/2162402X.2024.2412371.","journal-title":"Oncoimmunology"},{"issue":"12","key":"8299_CR272","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","volume":"38","author":"L Volta","year":"2024","unstructured":"Volta L, Myburgh R, Pellegrino C, Koch C, Maurer M, Manfredi F, et al. Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells. Leukemia. 2024;38(12):2598\u2013613. https:\/\/doi.org\/10.1038\/s41375-024-02409-1.","journal-title":"Leukemia"},{"issue":"1","key":"8299_CR273","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","volume":"14","author":"H Zhang","year":"2021","unstructured":"Zhang H, Hu Y, Shao M, Teng X, Jiang P, Wang X, et al. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. J Hematol Oncol. 2021;14(1):113. https:\/\/doi.org\/10.1186\/s13045-021-01117-y.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"8299_CR274","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","volume":"11","author":"M Zhang","year":"2025","unstructured":"Zhang M, Fu S, Feng J, Hong R, Wei G, Zhao H, et al. Dasatinib and CAR T-Cell therapy in newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. JAMA Oncol. 2025;11(6):625. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0674.","journal-title":"JAMA Oncol"},{"key":"8299_CR275","doi-asserted-by":"publisher","unstructured":"Baur K, Heim D, Beerlage A, Poerings AS, Kopp B, Medinger M, et al. Dasatinib for treatment of CAR T-cell therapy-related complications. J Immunother Cancer. 2022;10(12):e 5956. https:\/\/doi.org\/10.1136\/jitc-2022-005956.","DOI":"10.1136\/jitc-2022-005956"},{"key":"8299_CR276","doi-asserted-by":"publisher","unstructured":"Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv. 2025;11(4):eads 3403. https:\/\/doi.org\/10.1126\/sciadv.ads3403.","DOI":"10.1126\/sciadv.ads3403"},{"issue":"1","key":"8299_CR277","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/2643-3230.BCD-23-0258","volume":"6","author":"S Jambon","year":"2025","unstructured":"Jambon S, Sun J, Barman S, Muthugounder S, Bito XR, Shadfar A, et al. CD33\u2013CD123 IF-THEN gating reduces toxicity while enhancing the specificity and memory phenotype of AML-Targeting CAR-T cells. Blood Cancer Discov. 2025;6(1):55\u201372. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0258.","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"8299_CR278","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1021\/acsnano.4c01597","volume":"18","author":"L Zhu","year":"2024","unstructured":"Zhu L, Man C, Harrison RES, Wu Z, Limsakul P, Peng Q, et al. Engineering a Programmed Death-ligand 1-targeting monobody via directed evolution for SynNotch-gated cell therapy. ACS Nano. 2024;18(11):8531\u201345. https:\/\/doi.org\/10.1021\/acsnano.4c01597.","journal-title":"ACS Nano"},{"issue":"12","key":"8299_CR279","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng R, Shen K, Liang S, Lyu Y, Zhang S, Dong H, et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol Immunol. 2024;21(12):1491\u2013504. https:\/\/doi.org\/10.1038\/s41423-024-01228-9.","journal-title":"Cell Mol Immunol"},{"key":"8299_CR280","doi-asserted-by":"publisher","unstructured":"Allen GM, Frankel NW, Reddy NR, Bhargava HK, Yoshida MA, Stark SR, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba 1624. https:\/\/doi.org\/10.1126\/science.aba1624.","DOI":"10.1126\/science.aba1624"},{"issue":"1","key":"8299_CR281","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-025-00764-4","volume":"13","author":"V Dewaker","year":"2025","unstructured":"Dewaker V, Morya VK, Kim YH, Park ST, Kim HS, Koh YH. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. Biomark Res. 2025;13(1):52. https:\/\/doi.org\/10.1186\/s40364-025-00764-4.","journal-title":"Biomark Res"},{"key":"8299_CR282","doi-asserted-by":"publisher","unstructured":"Abdalla AME, Miao Y, Taha YA, Meng N, Ouyang C. Strategies of AI-Driven CAR-T cell therapy towards solid tumours. Immunology. 2026. https:\/\/doi.org\/10.1111\/imm.70124.","DOI":"10.1111\/imm.70124"},{"key":"8299_CR283","doi-asserted-by":"publisher","unstructured":"Chen Y, Ren R, Yan L, Zhou Y, Sun R, Song H, et al. From bench to bedside: emerging paradigms in CAR-T cell therapy for solid malignancies. Adv Sci. 2025;12(40):e 5822. https:\/\/doi.org\/10.1002\/advs.202505822.","DOI":"10.1002\/advs.202505822"},{"issue":"13","key":"8299_CR284","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms25137231","volume":"25","author":"N Martarelli","year":"2024","unstructured":"Martarelli N, Capurro M, Mansour G, Jahromi RV, Stella A, Rossi R, et al. Artificial Intelligence-powered molecular docking and steered molecular dynamics for accurate scFv selection of anti-CD30 chimeric antigen receptors. IJMS. 2024;25(13):25. https:\/\/doi.org\/10.3390\/ijms25137231.","journal-title":"IJMS"},{"issue":"5","key":"8299_CR285","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu S, Chen J, Wu T, Li L, Wang G, Wu H, et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 2024;34(5):386\u201388. https:\/\/doi.org\/10.1038\/s41422-024-00936-1.","journal-title":"Cell Res"},{"key":"8299_CR286","doi-asserted-by":"publisher","unstructured":"Ansari MS, Chauhan V, Singh A, Akhtar A, Chaudhary N, Tyagi R, et al. AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape. Nat Commun. 2026;17(1). https:\/\/doi.org\/10.1038\/s41467-025-68272-5.","DOI":"10.1038\/s41467-025-68272-5"},{"key":"8299_CR287","doi-asserted-by":"publisher","first-page":"1635159","DOI":"10.3389\/fimmu.2025.1635159","volume":"16","author":"JC Baena","year":"2025","unstructured":"Baena JC, Victoria JS, Toro-Pedroza A, Arag\u00f3n CC, Ortiz-Guzman J, Garcia-Robledo JE, et al. Smart CAR-T nanosymbionts: archetypes and proto-models. Front Immunol. 2025;16:1635159. https:\/\/doi.org\/10.3389\/fimmu.2025.1635159.","journal-title":"Front Immunol"},{"issue":"22","key":"8299_CR288","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.1182\/bloodadvances.2025016375","volume":"9","author":"M Wang","year":"2025","unstructured":"Wang M, Komanduri KV, Datta D, Patel A, Whitaker B, Belov A, et al. An AI model classifies risks of early relapse post\u2013CAR T-cell therapy in a multicenter real-world population with DLBCL. Blood Adv. 2025;9(22):5837\u201352. https:\/\/doi.org\/10.1182\/bloodadvances.2025016375.","journal-title":"Blood Adv"},{"key":"8299_CR289","doi-asserted-by":"publisher","unstructured":"Gong Y, Fei P, Zhang Y, Xu Y, Wei J. From multi-omics to Visualization and beyond: bridging micro and macro insights in CAR-T cell therapy. Adv Sci. 2025;12(20):e2501095. https:\/\/doi.org\/10.1002\/advs.202501095.","DOI":"10.1002\/advs.202501095"},{"key":"8299_CR290","doi-asserted-by":"publisher","unstructured":"Li G, Du R, Wang D, Zhang X, Wang L, Pu S, et al. Improved efficacy of triple-negative breast Cancer immunotherapy via hydrogel-based Co-delivery of CAR-T cells and mitophagy agonist. Adv Sci. 2025;12(14):e2409835. https:\/\/doi.org\/10.1002\/advs.202409835.","DOI":"10.1002\/advs.202409835"},{"issue":"2","key":"8299_CR291","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","volume":"9","author":"DA Zandaki","year":"2025","unstructured":"Zandaki DA, Selukar S, Bi Y, Li Y, Zinsky M, Bonifant CL, et al. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. Blood Adv. 2025;9(2):270\u201379. https:\/\/doi.org\/10.1182\/bloodadvances.2024014027.","journal-title":"Blood Adv"},{"issue":"17","key":"8299_CR292","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"issue":"1","key":"8299_CR293","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41467-023-44447-w","volume":"15","author":"D Sevenler","year":"2024","unstructured":"Sevenler D, Toner M. High throughput intracellular delivery by viscoelastic mechanoporation. Nat Commun. 2024;15(1):115. https:\/\/doi.org\/10.1038\/s41467-023-44447-w.","journal-title":"Nat Commun"},{"issue":"10","key":"8299_CR294","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"8299_CR295","doi-asserted-by":"publisher","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, et al. Generic Diagramming platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53(D1):D1670\u201376. https:\/\/doi.org\/10.1093\/nar\/gkae973.","DOI":"10.1093\/nar\/gkae973"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08299-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:02:17Z","timestamp":1784851337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":295,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8299"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08299-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"953"}}